I’m writing from Amsterdam, where this past week, the Being Patient editorial team has been reporting on the biggest news from the Alzheimer’s Association…
We arrived at the emergency vet at 1 a.m. Our 10-month-old kitten, Pippin, had started breathing oddly earlier in the day but we thought…
American pharmaceutical company Eli Lilly announced in May 2023 that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to…
Last week I had the opportunity to be the guest speaker of Grand Rounds at the Memory and Aging Center at the University of…
After almost two decades of stagnation, two new drugs for Alzheimer’s have hit the market in the last three years. The approval of Biogen…
Despite decades of study, the underlying cause of Alzheimer’s continues to evade scientists. Because it’s such a mystery, there are only six drugs approved for…
In June, the Food and Drug Administration will decide whether to grant full approval to Biogen and Eisai’s anti-amyloid Alzheimer’s drug Leqembi (generic name…
UPDATE: 3 March 2024, 8:21 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
According to drugmaker Eli Lilly, the FDA has rejected the company’s application for the FDA’s “Accelerated Approval” designation for experimental Alzheimer’s drug donanemab. The…
Update: As of July 6, 2023, the drug has full, traditional FDA approval. Today, the Food and Drug Administration approved Leqembi (generic name lecanemab), a…
The approval of the controversial anti-amyloid drug Aduhelm last year marked a major milestone for Alzheimer’s research — it became the first new drug…
Much anticipated Phase 3 data for Alzheimer’s drug lecanemab was presented at CTAD in 2022, showing the drug is as safe as the placebo…
Update 27 January, 2023: In January 2023, lecanemab was granted accelerated approval by the FDA and made available to patients under the brand name…
Most Alzheimer’s treatments on the market today help manage symptoms, like memory loss — but they don’t get at the root cause. Roche hoped their…
There were more than 140 experimental Alzheimer’s drugs in clinical trials as of the start of 2022. On the one hand, this number inspires…